Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs

Podobne knjige/članki

• Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor
  od: Nishino, Mizuki, et al.
  Izdano: (2013)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  od: Nishino, Mizuki, et al.
  Izdano: (2012)
• Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression
  od: Nishino, Mizuki, et al.
  Izdano: (2013)
• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  od: Lo, Peter C., et al.
  Izdano: (2015)
• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
  od: Nishino, Mizuki, et al.
  Izdano: (2013)